Cost-effectiveness analysis of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma based on the NEOCRTEC5010 trial

Esophageal cancer is a highly lethal disease, especially in developing countries. China has been a high-incidence area of esophageal cancer for many years and accounts for over 50% of the global morbidity and mortality [1]. The two major histological types of esophageal cancer are squamous cell carcinoma (ESCC) and adenocarcinoma, and there is a striking geographical variation in the incidence of the esophageal cancer subtypes. In China, approximately 90% of patients with esophageal cancer are diagnosed with ESCC [2].

Source: Radiotherapy and Oncology - August 16, 2019 Category: Radiology Authors: Mei Zhan, Hanrui Zheng, Yu Yang, Ting Xu, Qiu Li Tags: Original Article Source Type: research